Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression

[11] Li T(2016)Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia N Engl J Med 375 740-2390

[12] Li Y(2017)Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation N Engl J Med 377 454-38

[13] Xing H(2018)FLT3 inhibitors in acute myeloid leukemia J Hematol Oncol 11 133-2146

[14] Sun H(2006)IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples Can Res 66 4843-804

[15] Yu J(2016)Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status Cancer Res 76 574-1718

[16] Li Y(2018)Metabolism of an oxime-linked antibody drug conjugate, AGS62P1, and characterization of its identified metabolite Mol Pharm 15 2384-6964

[17] Zhang D(2015)T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 Clin Exp Metastasis 32 29-566

[18] Wan D(1995)Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma Blood 85 2139-254

[19] Jiang Z(2019)Antibody-drug conjugates for cancer Lancet 394 793-491

[20] Daver N(2018)Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study Artif Cells Nanomed Biotechnol 46 1708-2978

[11] Li T(2016)Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia N Engl J Med 375 740-2390

[12] Li Y(2017)Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation N Engl J Med 377 454-38

[13] Xing H(2018)FLT3 inhibitors in acute myeloid leukemia J Hematol Oncol 11 133-2146

[14] Sun H(2006)IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples Can Res 66 4843-804

[15] Yu J(2016)Abstract 574: AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status Cancer Res 76 574-1718

[16] Li Y(2018)Metabolism of an oxime-linked antibody drug conjugate, AGS62P1, and characterization of its identified metabolite Mol Pharm 15 2384-6964

[17] Zhang D(2015)T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 Clin Exp Metastasis 32 29-566

[18] Wan D(1995)Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma Blood 85 2139-254

[19] Jiang Z(2019)Antibody-drug conjugates for cancer Lancet 394 793-491

[20] Daver N(2018)Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study Artif Cells Nanomed Biotechnol 46 1708-2978